527680-56-4

PHA 568487 treatment reduces mouse cognitive decline caused by aseptic bone fracture by promoting inflammation resolution. PHA 568487 (PHA; 0.8 mg/kg; injected intraperitoneally) reduces infarct volume and TUNEL positive neurons in the peri-infarct regions of permanent middle cerebral artery occlusion (pMCAO) and pMCAO+tibia fracture mice^[2].
The role played by a7 receptors on neuroinflammation is supported by the decrease of [¹⁸F]DPA-714 binding in ischemic rats treated with the a7 agonist PHA 568487 at day 7 after MCAO^[3].
PHA 568487-treated ischemic rats show a significant reduction of the cerebral infarct volumes and an improvement of the neurologic outcome compared with non-treated MCAO rats^[3].